Wilex changes CFO
07.08.2012 - German biotech Wilex AG will change its executive management board. Chief Financial Officer Peter Llewellyn-Davies has to leave the company upon the expiration of his six year contract on September 1st. Jan Schmidt-Brand will take over.
Schmidt-Brandt is currently the Managing Director of Wilex's subsidiary Heidelberg Pharma GmbH. He was the CEO of Heidelberg Pharma AG until the company was acquired by Wilex. From 1997 to 2001, he was Managing Director of the Austrian BASF-Pharma subsidiary, EBEWE Arzneimittel GmbH, where his responsibilities included finance and controlling. Prior to this, he held several positions at the BASF Group for a total of eight years, most recently as an executive in the central tax department. Schmidt-Brand is a member of the Board of BioDeutschland and Head of the Finance and Tax working group. Llewellyn-Davies will pursue new activities but continues to act as an advisor for the company. He will fully manage and complete the capital measure announced by Wilex on August 3. “Mr Llewellyn-Davies has made important contributions to the development of Wilex since joining the company prior to its IPO in 2006. We would like to thank him very much for his collaboration, which was both constructive and successful, and wish him great success in realizing his objectives”, said Professor Christof Hettich, Chairman of the Supervisory Board.http://www.european-biotechnology-news.com/people/bio-people/2012-2/peter-llewellyn-davies.html